CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an immunotherapy boost help fight stomach cancer?
Disease control Recruiting nowThis clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Proton beam vs. X-Ray radiation: which is better for esophageal cancer?
Disease control Recruiting nowThis study compares two radiation techniques for people with stage I to IVA esophageal cancer: proton beam therapy (which uses protons) and intensity modulated photon radiotherapy (which uses X-rays). The goal is to see which one works better at helping people live longer and cau…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New chemo combo tested to extend life in Hard-to-Treat stomach and esophageal cancers
Disease control Recruiting nowThis study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo aims to boost esophageal cancer treatment before surgery
Disease control Recruiting nowThis study is for people with stage I to III esophageal or gastroesophageal junction cancer. It tests whether giving a shorter, higher-dose radiation treatment along with chemotherapy (FOLFOX) before surgery can kill more cancer cells. The goal is to see if this approach leads to…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental nanoparticle boosts radiation against esophageal cancer
Disease control Recruiting nowThis early-phase trial tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation to destroy cancer cells. It is given alongside standard chemotherapy for people with stage II–III esophageal adenocarcinoma. The main goals are to find the safest do…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a heart drug boost cancer treatment? new trial tests propranolol with chemo and immunotherapy
Disease control Recruiting nowThis phase 2 trial is testing whether adding propranolol, a common beta-blocker used for heart conditions, to standard chemotherapy and pembrolizumab (an immunotherapy) can improve treatment response in people with advanced esophageal or gastroesophageal junction cancer that cann…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC